Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.57
+0.09006.08%
Post-market: 1.570.00000.00%18:42 EDT
Volume:351.28K
Turnover:546.53K
Market Cap:50.27M
PE:-0.39
High:1.57
Open:1.50
Low:1.50
Close:1.48
Loading ...

Outlook Therapeutics announces presentation of data from NORSE EIGHT

TIPRANKS
·
23 Jan

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results From Norse Eight Clinical Trial Evaluating Ons-5010 for the Treatment of Wet Amd

THOMSON REUTERS
·
23 Jan

Outlook Therapeutics Inc - Company on Track for Bla Resubmission in Q1 2025

THOMSON REUTERS
·
23 Jan

Chardan Capital Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)

TIPRANKS
·
21 Jan

Outlook Therapeutics Price Target Maintained With a $12.00/Share by Guggenheim

Dow Jones
·
17 Jan

Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD

MT Newswires Live
·
17 Jan

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Benzinga
·
17 Jan

Outlook Therapeutics Inc - Bla Resubmission on Track for Q1 2025

THOMSON REUTERS
·
16 Jan

Outlook Therapeutics: Entered Into Agreements for Warrant Inducement Transaction Expected to Result in up to $20.4 Mln in Gross Proceeds

THOMSON REUTERS
·
16 Jan

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of Norse Eight Clinical Trial

THOMSON REUTERS
·
16 Jan

Outlook Therapeutics Inc - Ons-5010 Demonstrated Non-Inferiority to Lucentis at 12 Weeks

THOMSON REUTERS
·
16 Jan

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

GlobeNewswire
·
16 Jan

Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies

TIPRANKS
·
29 Dec 2024

Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment

Dow Jones
·
28 Dec 2024

Outlook Therapeutics' Annual Loss Per Share Narrows in FY24; Shares Up

MT Newswires Live
·
27 Dec 2024

BRIEF-Outlook Therapeutics Reports Financial Results For FY 2024 And Provides Corporate Update

Reuters
·
27 Dec 2024